Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Camurus, Audiocast, Q4'24

By Inderes2/13/2025, 1:00 PM
Camurus

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Operator
00:07 - 00:26

Welcome to Camurus' Q4 report 2024 for the first part of the conference call. The participants will be in listen-only mode during the question and answer session. Participants are able to ask questions by dialing Pound Key five on the telephone keypad. Now I will hand the conference over to CEO Fredrik Tiberg. Please go ahead.

Fredrik Tiberg
00:26 - 03:02

Thank you so much, Agneta. And good day, everyone, and welcome to Camurus' full-year and fourth-quarter earnings call. Before starting, please note our forward-looking statements. So we will begin the presentation today with some short business highlights. Then review the financial performance followed by commercial and R&D updates. And of course, then a Q&A. As previously mentioned, I'm joined on the call by Jon Garay, CFO, and Richard Jameson, Chief Commercial Officer. Camurus had a rewarding 2024 with good performances across the business. This resulted in high growth and profitability alongside advances in key pipeline programs. In the US, importantly, we remain on track to deliver our five-year vision of fivefold revenue growth from 2022 and an approximate 50% operating margin in 2027. As a reflection of the solid performance during the year, we delivered continued strong operating revenue growth as well. As you can see on the right-hand side here, we maintain sustainable, high profitability. Our fourth-quarter results exceeded previous estimates, with sales growing at a double-digit rate in owned territories and finishing the first full year with a strong fourth quarter. Additionally, we established a fully operational US commercial organization to prepare for the launch of CAM2029 in acromegaly. On the development side, regulatory reviews of CAM2029 continued in the US and the EU with a temporary setback in the US in the form of a complete response letter from the FDA relating to an inspection of a third-party manufacturing facility. I will come back to this later in the presentation. In parallel with the regulatory reviews, our clinical studies, Sorrento and Positano, continued to advance. And before the new year, we initiated a new clinical study of our once-monthly semaglutide GLP-1 product. On the corporate side, we delivered solid financial performance, positioning the company for further expansion and growth in 2025. And with this short introduction, I'll hand it over to John for a financial update.

Jon Garay Alonso
03:03 - 08:49

Thanks a lot, Fredrik. And good afternoon, everyone. During the quarter, Camurus continued its development, delivering strong growth and financial performance. Now, I would like to share the key financial highlights of this quarter. At the end of the quarter, Camurus achieved 553 million in total revenue, delivering a growth of 48% compared to the same period last year, with product sales of 469 million, growing 28% compared to the prior year and 11% compared to the prior quarter. Additionally, sales in the United States represented an SEK 83 million royalty income, growing 43% versus prior quarters. Looking at full-year results, Camurus reached 1,868 million in total revenue, representing a growth of 9% versus the prior year. Excluding one-time revenues in 2023 related to the bridge study approval in the US by the FDA. Total revenue grew 42% versus the prior year, and the royalty represented 212 million SEK during 2024. The company achieved an earnings per share after dilution of 7.20 Swedish kronor, equivalent to a profit after tax of 429 million. And the company's cash position progressed positively, ending at 2.85 billion SEK. Moving to the next slide. We can see the main components of our profit before taxes. Company gross margin reached 94% in the quarter, representing an improvement of 267 basis points versus the same period in the prior year, driven by three major factors. Firstly, supply chain efficiencies driven by volume and scale-up represented 181 basis points. Secondly, 96 basis points are driven by loyalty programs. And thirdly, ethics represented a negative impact of 10 basis points. Total opex reached 357 million, representing a 4% decrease versus the same period in the prior year, driven by the following factors. Marketing and distribution investments were aimed at supporting market penetration in owned territories. Expansion of new markets and US operations grew 40% to 157 million SEK. Administrative expenses aligned with corporate evolution to substantiate company development grew 48% versus the same period last year to 25 million SEK. R&D investment reached 167 million, decreasing 27% versus the same period in the prior year, driven by lower social security costs related to long-term safety plans and lower study costs in our clinical trials. Equivalent to 37% of total company revenue during the quarter. The company explored a potential transaction, including one-time expenses of 8,000,006 SEK regarding advisory fees that are reported in other operating expense lines. Company profit before taxes reached 186 million. Growing by 204 million versus Q4 2023. On a full-year basis. Company profit before taxes reached 553 million, which, excluding one-time revenue impact, represents an improvement of 409 million, increasing 286% versus 2023. Company cash position at quarter end was 2.85 billion. Camurus improved its cash position by 101 million during the quarter, driven by the following four factors. Firstly, company operations generated 166 million SEK. Secondly, the third window of the ESOP 2024 program generated 18 million. Thirdly, working capital consumed 63 million. Secondly, and fourthly, investing activities required 20 million SEK. The growth trajectory of Camurus shows no sign of slowing down. Moving now to 2025, the company has considered the following factors when providing financial guidance for the year. Market conditions. Continued investments aligned with the Strategic Vision 2027, in which we plan for R&D to remain approximately flat at the level of 0.65 billion SEK, with an incremental investment of approximately 0.35 billion SEK to fully deploy US Operation Launch globally and support company growth. Social security costs regarding company long-term safety programs will vary with the shared evolution. And from a capital expenditure point of view. The company will invest about 0.2 billion SEK in the next two years to develop a second manufacturing facility to enhance production capabilities and support new product launches. Camurus's full year 2025 outlook is as follows. Total revenues in the range of 2.7 to 3 billion, representing a growth of 45% to 61%. Profit before tax is expected to be in the range of 0.9 to 1.2 billion SEK, representing an increase of 63% to 117%. All in all, Camurus closes 2024 with a strong financial position. Solid operational performance, interesting growth opportunities, and the company remains on track to deliver 4.5 billion. Total revenue growth at approximately 50%. Operating margin by 2027. Having said that, I would like to pass the word to Richard. Thank you everyone for your attention.

Operator
08:50 - 12:04

Thank you, John. The year finished strongly with sales of 469 million SEK, which was 11% higher than the previous quarter and 28% over the previous year. For the full year, sales reached 1.65 billion SEK, a growth of 27% compared to the previous year. And at the end of the year, we estimated 60,000 patients were currently being treated with Buvidal in the EU. This was led by the large European markets, including the UK, France, Germany, and Spain. The strong performance was a result of continued execution of key programs that drive penetration and improve access to Buvidal, resulting in continued market share gain and new patient recruitment across all geographies in Australia. This is now established as a first-line treatment. The market share of long-acting buprenorphine in Australia is now estimated at 32% of all patients and has clear leadership in this segment. This is supported by the efforts to improve capacity and access for patients. For example, with a growing number of pharmacies that have now been trained or are now administering Buvidal, which creates space for new patients at clinics. Our market expansion continued, and in the quarter we had three new reimbursement approvals that were received in Switzerland, Portugal, and Luxembourg and were launched in early 2025 in those countries. Additionally, four other regulatory applications are under review. Now moving across to the US. First, a reminder of the US market, where there are an estimated 6 to 7 million people with opioid use disorder, of which an estimated 2.3 million seek treatment in a year, and 1.8 million of those are on buprenorphine. In the fourth quarter, Brixadi had strong growth. Net sales grew 43% versus the previous quarter, resulting in royalties of 83 million SEK, and totaling 212 million SEK for the full year. The launch continues to outperform previous product launches in this segment. Patient capture was primarily from the large sublingual buprenorphine segment, while the remainder came from transfers from other long-acting products and direct initiations into treatment from Brixadi. So, 15 months from the initial launch, Brixadi's market share has reached approximately 25% of the long-acting segment, and the market share potential for it is estimated to be above $1 billion. Now, the support for both the evidence base for effectiveness in different treatment settings and the economic outcomes continues to grow. In the quarter, we have three important publications. First was an exploration of treatment outcomes through quantitative urine measures that emphasized the treatment effect in patients using high levels of opioids. Secondly, a naturalistic study showed a clear preference from patients for Brixadi injection over other long-acting injectables. And finally, a paper that explored healthcare professionals' perceptions showed high satisfaction for long-acting buprenorphine compared to both methadone and daily sublingual buprenorphine. And this growing evidence base continues to be shared through our wide-ranging medical education programs and at leading congresses. And on that note, I'll hand back to Fredrik for an R&D update.

Fredrik Tiberg
12:06 - 19:16

Okay. Thank you. I will start with CAM2029 and the developments across the three target indications. Acromegaly, gastric pancreatic neuroendocrine tumors, and polycystic liver disease (PLD) in acromegaly. The two Phase Three trials have been successfully completed with positive results. The last few patients in the extension study of ACROINNOVA 2 will complete treatment in May 2025, followed by data readout and results in gastroenteropancreatic neuroendocrine tumors. Treatment of patients in the randomized, active-controlled Sorrento trial continued to progress with generally positive experiences communicated from participant investigators and clinical staff based on an indication of a slower than expected rate of tumor progression in the study, especially in this study population where the majority had advanced disease of grade 2 or 3 when included in the trial. The estimated time for reaching the target of 194 events for reading out the primary results was updated to late 2025 or early 2026. In polycystic liver disease, the last patients entered into the final stages of the randomized, placebo-controlled Positano trial, and they are now in the process of completing the core phase of the study, with primary results expected in the second quarter of this year. On the regulatory side, we looked forward to an FDA approval on the PDUFA date of the 21st of October, after late-stage labeling discussions with the agency. Instead, we received a complete response letter from the FDA, which solely related to a GMP inspection at the third-party manufacturing facility. No concerns were related to CAM2029's safety, efficacy, or chemistry, manufacturing, and controls, and the manufacturer has responded to the observations and is currently waiting for the FDA to share the establishment inspection report following a recent OAI classification. This will be used to decide the timing of the NDA resubmission, which tentatively is planned for the first half of this year. In the EU, our market authorization application advanced according to plan and we expect the decision. The CHMP opinion is expected around mid-year 2025, followed by a decision by the European Commission. On the medical side. Efforts have been focused on medical affairs and disseminating results and data from our phase three studies. The main result of the Nova one trial was published in the Journal of Clinical Endocrinology and Metabolism in October, and multiple meeting abstracts and new manuscripts have recently been completed and submitted. Our medical and MSL teams have been very active in informing about CAM2029, as well as Camurus more generally, to the broader acromegaly community and planning for several important events in 2025. Camurus will be present at key scientific conferences and meetings in 2025, with presentations and symposia. As shown in this slide. Here we are experiencing a large interest in learning more about the product and doing everything we can to make it available to patients as soon as possible. On the commercial side, we continue to prepare for the launches in the US as well as in select countries in the EU. The opportunity for 2029 is substantial, with potential peak sales across indications and geographies estimated to exceed 2 billion USD annually. In the early development pipeline. We advanced a number of different programs for long-acting initiatives, for instance, including a monthly semaglutide formulation. A clinical trial application was approved in the fourth quarter, and the first patients were enrolled before the end of the year. The study is now up and running, evaluating pharmacokinetics. Pharmacodynamics, including weight loss and safety of CAM2056 versus the current commercially available weekly semaglutide in participants with overweight or obesity who are otherwise healthy. In the first part of the study, we are comparing two dosing schedules of CAM2056 against the dose titration to the labeled schedule, which exists for weekly semaglutide. Following this, different escalation regimes will be explored. Before wrapping up, I can also mention that we have finalized the setting up of our new headquarters in London, where we are currently sitting, and we have built here a state-of-the-art lab tailored to our different needs from early to late-stage development. And this will, of course, be used here to support our planned business expansion during the coming years. Based on a very successful 2024, we have laid the foundation for 2025, where we expect to see increased market penetration and the acceleration of exciting sales in the US. Obtain approvals for CAM2029 in acromegaly, deliver clinical results for CAM2029 in polycystic liver disease, and also for the new program, CAM2056. In addition, we plan to diversify our business through business development activities, overall contributing to a positive financial outlook for 2025, which we have shared earlier today and in this presentation by John. Regarding the 2027 vision, we continue progressing in all four areas and remain on track to meet our target of revenue, US commercialization, pipeline progress, and operating margin. So with this as a final note, I hand over the call to our operator for Q&A.

Operator
19:18 - 19:23

Thanks. And our first question comes from the line of Victor. Please go ahead.

Fredrik Tiberg
19:27 - 19:28

Yes. Hi and.

Operator
19:28 - 20:41

Thanks. Thanks for taking my questions. I had a question regarding your guidance. Um, you gave quite a lot of detail on the cost side, but I just wanted to get some more detail on the total revenue guidance. I'm, so, so looking at any specific markets that you see accelerating growth here in 2025. You previously talked about Germany and the challenges with reimbursement for long-acting treatments. So I just wonder if there's any update here or in other key geographies. Also on polycystic liver disease for 2029. It looks quite like a de-risked study. Um, given the data that we have, you know, some of that in LA, but I just wondered what the next steps would be. And how would that look in terms of size, control arm, etc.? And just finally, I also wondered about your M&A strategy, as you're being quite forward about that. You look for M&A opportunities. So, any comment if that is still the case and what kind of assets do you think could fit within your company at this stage? Thank you.

Fredrik Tiberg
20:41 - 21:07

Thank you, Victor. I mean, on the first question. I think we continue to see significant momentum in the major European countries, as Richard mentioned earlier. So that's and that includes, of course, Germany, the UK, but also more increasingly we see progress in Spain, France, and other countries. So, that's, I think, our focus area from a geographical perspective. Richard, any more details you would like to add?

Operator
21:08 - 21:08

Anything.

Fredrik Tiberg
21:08 - 21:09

That comes up.

Jon Garay Alonso
21:10 - 22:51

When it comes to polycystic liver disease? Of course. Uh, that is a very interesting study for us. And this is an indication where there is currently no treatment. So, uh, I think you should regard this as, as we have said, a phase 2 or 3 study in the US. We do not believe we will. It will not surface with just one study. There's this potential in Europe. But, uh, our idea is to base it on the data from the phase two trial from Positano. We should formulate the phase three trial, which we are currently planning. Um, and, uh, we cannot say anything about the details here. We have been working on it for quite some time now and are planning the design and the timelines for the study. Uh, and I think we have a really good starting point here, but we need the data before we can finalize this and determine the powering of the trial and so forth. Uh, but so far, uh, we have done a lot of work and, uh, I think overall it looks interesting. So, any follow-up questions on that, Victor, before we move on to the M&A strategy? Oh yes. Sorry. I mean, the M&A strategy remains, as previously communicated, we are chiefly targeting commercial assets or pre-commercial assets that are synergistic to our current pipeline or commercial organizations in the different territories where we operate. Victorine.

Operator
22:51 - 22:53

Thank you. I will jump back into the queue. Thank you.

Fredrik Tiberg
22:54 - 22:55

Thank you.

Operator
22:56 - 23:06

As a reminder, if you wish to ask a question, please press the Pound key followed by five on your telephone keypad. The next question is from Kristoffer from SEB. Please go ahead. Your line is open.

Fredrik Tiberg
23:08 - 23:41

Uh, hi there, Kristoffer Udy from SCB. Thanks for taking my questions. Um, I guess the first one, uh, is on the regulatory situation. Just, you know, if there's any more clarity you could possibly give, um, you know, some insight into the reasons for the OAI classification. Um, and, you know, is the, uh, establishment inspection report all that you need to be able to refile or, um, you know, what else might be necessary? What? And what if they say there are still deficiencies? What? What happens then?

Jon Garay Alonso
23:42 - 25:32

Yeah, that's a very good question. I mean, overall, um, just to go back, we were expecting to get the classification, of course, as I said much earlier. So in mid-December and so forth, it's been quite a, yeah, it's an interesting dynamic right now at the agency. Um, if I put it that way, however, I think we have a clear understanding; we know, of course, what the 483 says and what our manufacturer does. And they were quite satisfied with the state of those being addressed. We are not completely clear on the review history. And that's why we need the EIR, because we need to get clarity on whether or not there are any questions that are outstanding. We suppose so, and if so, what? What are the actions we believe are necessary? I think that, I mean, having studied the 483, there is nothing that seems to be, from a time perspective, very extensive in terms of mitigating. So, I think that we are in good shape there, but we simply need the EIR to be able to better clarify whether or not we have resolved everything or if there is anything left to address by the manufacturer. On a positive note, we don't have anything, of course, with regards to the product; we had no objections and no real comments, and we were ready with labeling. So, so we should be able to move very quickly in terms of refiling.

Operator
25:34 - 26:08

Okay. Uh, and then if I could ask, uh, another question around the guidance, um, I guess in light of this, is it fair to assume that you're assuming an immaterial contribution from anglaise in 2025 and then, uh, how about Brixadi? Because last year you had sort of indicated, indirectly, that the guidance from your partner was extremely conservative. Uh, if we try to back that out for this year, what are you expecting for growth in 2025?

Fredrik Tiberg
26:09 - 26:10

Well.

Jon Garay Alonso
26:11 - 26:59

No, I think that, uh, I mean, starting with the first question, you can regard your claims to be quite immaterial in terms of its contribution when it comes to. I'm not really sure about the comment you made there regarding the partner, but, uh, I think that, uh, you know. Overall, they probably have quite realistic views. I cannot comment on their views, and therefore I don't want to split the two components. So, uh, I think that you can regard a majority or a very large part of our guidance to be constituted in terms of revenue, of the 2 billion, but we are not providing them separately at this point.

Operator
27:01 - 27:10

Fair enough. Um, in terms of, I mean, you had 4,000 patients added this last quarter. Is that the new floor?

Fredrik Tiberg
27:11 - 27:41

We don't have a floor. I mean, we have a target and we are tracking towards the target, which is 100,000 patients in 2027. Uh, we don't have a floor. I think it will vary, you know, by quarter. So we are not foreseeing that we will have a, you know, a constant pattern or have a floor. It will be varying by quarter, as we have seen previously. Um, and I think that's all we can say for now. Yeah. But our target remains.

Operator
27:41 - 27:41

Yes.

Fredrik Tiberg
27:44 - 28:10

Um, if I could just ask a couple more questions around the specific markets, and I apologize, I had trouble hearing the answer on the remuneration in Germany, but let's say starting with that. And do you have any insight into, you know, uh, yeah, the reasons around that timing.

Jon Garay Alonso
28:11 - 29:23

We know the process because we are a commercial company. We have to have a completely hands-off approach here. So, we are just following this from the sidelines. Uh, we understand that there is an agreement among the different parties that are involved, which include the insurance providers. It is, of course, the medical community as well as the political dimension. And what we have understood is that there is a consensus that they need to change the current, uh, remuneration, um, basis. And we think that would be very good in terms of providing German patients with much better treatment options. We understand from the latest updates that there are still expectations that this will be finalized in 2025. However, all of these processes are externally driven. Uh, so, but I think there is a positive view on that and positive development.

Operator
29:25 - 29:47

Got it.

Fredrik Tiberg
29:49 - 30:53

Uh, Christophe, I don't think—I mean, in terms of performance, we have seen very strong performances across markets. So we're pleased with all of these markets that I mentioned. And actually, I mean, we're seeing consistent growth. There might be one or two markets that are experiencing a slower pace this quarter. But overall, very good performances. Uh, so we are pleased with that. And we are also pleased with the fact that we are now able to go in and launch the products in three more countries. And we have processes ongoing in other countries as well. So we look forward to the market expansion possibilities that have come up now in both Portugal and Switzerland. I mean, Luxembourg is a very small country, but they still have approximately a thousand patients there. So, that's a very important part. And we will ensure that the market expansion process will continue here going forward. But I can't comment on specific countries.

Operator
30:55 - 30:57

Yep. That's all from me. Thank you.

Fredrik Tiberg
30:57 - 30:58

Thank you so much.

Operator
30:59 - 31:05

The next question is from Oscar Lamb, representing Bryan Garnier. Please go ahead.

Fredrik Tiberg
31:08 - 31:46

Hi, Tim, it's also Oscar here from BG. Thank you for taking my question. So, I was wondering if you could provide some granularity on what percentage of market share you have in major European markets. And if you believe that the uptake in patients at its treatments this quarter will be maintained in the coming year, taking into account the new markets that are to be included. And then my second question would be on the obesity trial. Um, and more precisely, after how many weeks and treatments will you measure the weight loss? And then as a follow-up on that, what would be your estimated threshold for efficacy that would convince you to push the program forward? Thank you.

Jon Garay Alonso
31:47 - 32:02

Yeah. Thank you. I mean, when it comes to the European markets, I think, you know, they vary from very high percentages to lower. But maybe, Richard, you can give a comment on the broad.

Operator
32:02 - 32:04

Yes, I mean, you mentioned Australia obviously.

Fredrik Tiberg
32:04 - 32:18

Before, um, and that one's there. And as Fredrik said, there's a range sometimes; it depends, of course, if those markets are hybrid markets or methadone-based, but we're making demands on the methadone. Uh, so yeah, I mean.

Jon Garay Alonso
32:18 - 32:18

There.

Operator
32:18 - 32:19

There is a range from.

Fredrik Tiberg
32:20 - 32:22

There's a range of up to.

Jon Garay Alonso
32:22 - 32:26

30% in some markets. And, you know, in high single digits in others.

Fredrik Tiberg
32:27 - 32:48

I think, you know, generally speaking, we can say that in the larger countries we are around in the low double-digit range or high single-digit range, whereas in the Nordic markets, for instance, we are up to 30-35%, even up to 60-70% in Finland, as we have said before.

Jon Garay Alonso
32:49 - 32:57

The Oscar race. Was your question specific to prisons or to general market shares?

Operator
33:00 - 33:02

To general market shares. Yeah.

Jon Garay Alonso
33:02 - 33:02

30% in some markets.

Operator
33:02 - 33:03

30% in some markets.

Jon Garay Alonso
33:04 - 33:06

And then the second one was GLP-1.

Fredrik Tiberg
33:07 - 34:40

Yeah. So in terms of the GLP-1 study, we are conducting that based on the toxicology work that we had done before. So currently, it's for the CAM2029 and CAM2056 groups. It's a 12-week period that we are studying. And of course, that includes, you know, any dose titration that you might be expecting in terms of the weight loss thresholds. So it's, of course, not one isolated topic we are looking at. We are looking at the complete holistic outcomes of the study. So I wouldn't comment on the actual exact threshold because it's still an early study, but certainly we expect to see data that will point us in the direction and that we will be able to use for our forthcoming larger trials. So I'm not concerned about that at all. I think we will, you know, be able to read out the results. And we have a study population of overweight and obese patients. So, we will see, you know, we'll get a good picture of the efficacy also on that note.

Operator
34:44 - 35:10

Okay. Super helpful. Thank you. And maybe just one additional question, uh, for the bulk study in the US, uh, since we're on the topic of the prison system, I mean, considering the large portion of patients that are in the prison system, uh, that would be eligible for treatments. I was wondering if at this stage you are really able to give a percentage of patients currently in the study that are coming from this system and how you view this segment moving forward in 2025 and onwards.

Fredrik Tiberg
35:10 - 35:59

I can say that the opportunity is, of course, very significant. We're talking about a large number of patients. It varies by the states because, I mean, in some states, there is an established treatment system in place. Whereas other states do not have it, so. And that's very much geographically dependent. But overall, the opportunity is very large. And obviously, um, Brixadi has only been in the market for just over a year. So, uh, this opportunity is, as I said, largely untouched in terms of penetration by Brixadi. Um, as you might imagine.

Operator
36:03 - 36:08

Yeah, that makes sense. Makes sense. Uh, that's all for me for now. Uh, thank you for taking my questions.

Fredrik Tiberg
36:10 - 36:14

The next question is from Mathias Bloom from Handelsbanken. Please go ahead.

Jon Garay Alonso
36:17 - 37:07

Thank you so much. Two questions, please. Um, so, so regarding the 2027 targets of 4.5 billion kroner in revenues. So historically, 3 billion was expected to be derived from Buvidal and 1.5 billion from CAM2029 with the acromegaly indication. But perhaps more importantly, in light of the market size for GEP-NET, the longer-term timing of events is around two. With that submission, as I understand it, targeted for the second half of 2026. I'm curious to hear if you still expect the 1.5 billion kroner contribution from CAM2029 by 2027, or is it fair to say that you perhaps expect a larger contribution from the order today, compared to those initial projections back in 2022 at R&D days? And then I have a follow-up.

Fredrik Tiberg
37:08 - 38:23

Yeah, so I'm not completely sure of your starting point here because at the R&D date we discussed, I think you're referring mainly to the contribution from there in your initial number, but so. And then the rest was a mixture. So, uh, no, we don't see it, uh, obviously, I mean, the acromegaly indication was and remains a small but important indication for us in terms of the CAM2029 franchise. But, uh, we still have a component coming in from CAM2029 into our 2027 estimates. Uh, we, I don't think we have commented on the size of that, John, have we? No. But, as we say, we remain on track to reach the targets. And, uh, so I, that's a mix of the different indications or the different products I referred to, but of course, the largest contribution comes from Brixadi and Vivitrol. All right. No discussion about that.

Jon Garay Alonso
38:27 - 38:37

Okay. There's a slide saying penetration 3 billion and late-stage product candidates one and a half. So maybe the one and a half is included. Yes, exactly.

Fredrik Tiberg
38:37 - 38:43

That's completely correct. Yeah. That's correct.

Jon Garay Alonso
38:43 - 38:57

Because I recall another peak sales potential for it all in euros. But, but maybe, um, historically provided. Correct me if I'm wrong, but I thought it was €170 million or something like that.

Fredrik Tiberg
38:58 - 38:59

But I don't.

Jon Garay Alonso
38:59 - 39:00

I don't know the specific point in time.

Fredrik Tiberg
39:00 - 39:04

I don't know where that number comes from, but anyway. Uh.

Jon Garay Alonso
39:06 - 39:06

Okay.

Fredrik Tiberg
39:07 - 39:07

Yeah.

Jon Garay Alonso
39:07 - 39:46

All right. The target is reconfirmed, uh, no matter what. Okay. And then secondly, um, looking at the FDA Orange Book, there are eight patents listed, with the longest extending to July 2032. So once CAM2029 is approved. Are there other patents beyond July 2032 that we should expect to be listed in the Orange Book for that product? Or are the timelines broadly the same? I know we have received Orphan drug designation for PLD from the FDA, but I'm not aware of such protection for GEP-NET, for instance, in the US market. So any clarification from you would be helpful.

Fredrik Tiberg
39:46 - 40:16

Absolutely. So, in terms of CAM2029, we have IP covering at least up to 2037. So, it's, I mean, there's different, uh, there is different IP for that. That covers all, of course, and potentially for longer time periods, uh, over time. So, we do have a number of filings that extend beyond the time frame.

Jon Garay Alonso
40:19 - 40:21

That's very helpful. Thanks so much. That's all for.

Fredrik Tiberg
40:21 - 40:23

Me. Um. Correct me if I'm wrong, but I thought it was €170 million or something like that.

Operator
40:24 - 40:35

The next question is from Victor, from Nordea. Please go ahead, Victor. Victor, please go ahead.

Jon Garay Alonso
40:35 - 41:12

Yeah. Sorry, I was on mute. Um, yes. Um, I just had a follow-up on, uh, the Sorrento trial also. Um, it seems like you have, you know, twice-monthly dosing in that trial. Um, is that a way to strengthen your position? Uh, boost your arm versus the control arm that's given once monthly? Um, do you expect, you know, higher bioavailability of the active compound and is that, so to speak? There is the readout of this trial, since it seems that retrospectively, it is the higher bioavailability and its correlation to progression-free survival that seems to drive your optimism around this trial. Uh, any comment here would be helpful.

Fredrik Tiberg
41:12 - 41:59

Thank you. I mean, the higher bioavailability is definitely consistent also in the NET (neuroendocrine tumor) indication. So in fact, the AUC, the area under the curve. So the total exposure during the treatment period is roughly about seven times higher for CAM2029 at the dosages given in the NET trial compared to the reference product. And then I have to, of course, refer to the reference product, because in the trial you have both the Tide and the Lanreotide products. So, but here I'm referring to the Oxford side. Was that?

Jon Garay Alonso
41:59 - 42:12

You know, with regards to Lanreotide, I just, um, any difference there you expect from, you know, the smaller trials that's been done or, or are they quite similar in your opinion.

Fredrik Tiberg
42:13 - 42:52

In terms of, I mean, if you ask the clinical community, they will tell you that they are quite similar. There are some studies, and they are all small. They indicate that in some cases, the ultratight arm provides better control, while in other cases, it is actually the opposite. So, I think we are trying to rely on the basic material that we have internally. But there is no good comparative data for hydroxyapatite, I would say, not in a large randomized prospective trial.

Jon Garay Alonso
42:57 - 42:59

Okay. That's very helpful. Thank you.

Fredrik Tiberg
42:59 - 43:00

Thank you.

Operator
43:00 - 43:05

The next question is from Patrick Link from the market. Please go ahead, Patrick.

Jon Garay Alonso
43:07 - 43:27

Thank you. Two short questions actually. Um, first of all, when it comes to your M&A strategy, you talked about commercial and pre-commercial assets that you're looking at. Could you elaborate a little bit on how pre-commercial you are actually looking? Are we talking late stage? Phase three or maybe phase two trials?

Fredrik Tiberg
43:28 - 44:08

Yeah, I mean, basically, late stage is our target. However, if there are, you know, certain reasons for looking at both the technology we possess, so to speak, and also our key interests, we could in some cases also look at phase two assets. And so, so, you know, we are not bound by any. But our clear preference and focus is on commercial stage or late stage. So I think that's my answer. Our answer.

Jon Garay Alonso
44:11 - 44:23

Okay. Good. And then, how far from where you are today on the different indications, would you be willing to look at assets?

Fredrik Tiberg
44:24 - 44:58

Well, we are looking at this from a scientific and commercial standpoint. Uh, basically, you know, we can operate within rare diseases. Uh, but our preference is for endocrinology assets over oncology. We have talked about endocrinology and CNS; those are the topics we are most interested in. Um, but not necessarily. You have to look broadly to find the most interesting targets.

Jon Garay Alonso
45:03 - 45:21

Okay, great. Then my last question is really about your new manufacturing facility that you're going to invest in. If you could elaborate a little bit on, is it? Uh, Europe. Is it the U.S.? Is it for existing products or new products? Can you give us more details?

Fredrik Tiberg
45:21 - 45:22

Us? No, I mean.

Jon Garay Alonso
45:23 - 45:24

You do.

Fredrik Tiberg
45:24 - 46:21

Yeah. When we did, I mean, it's when we did our capital raise. We mentioned that also in our use of proceeds. But I would like to say that our focus is on expanding our capacity, especially considering our plans to enhance the US manufacturing capabilities. And so, that's clear that we are not manufacturing ourselves. But that's one of the main aims. To give us flexibility. And we also have new programs entering the clinical phase. And those, of course, also require clinical manufacturing resources. So, so that's the target.

Jon Garay Alonso
46:26 - 46:29

Okay. Great. Yeah. Good. Thank you. That's all for me.

Operator
46:30 - 46:36

Yeah. The next question is from Donna at Pareto Securities. Please go ahead then.

Jon Garay Alonso
46:39 - 47:09

Hello and thank you for taking my questions. I think most have been answered; just one question on CAM2056: how the enrollment has been going, is that according to your expectations, and are you seeing any competition from competitors? Thank you.

Fredrik Tiberg
47:11 - 48:30

Well, I mean, uh, essentially, this is a phase one trial, although we have included the characteristics of overweight and obesity, but the volunteers are otherwise healthy. And I think we have had no problem in terms of recruitment. Um, so that's progressing well. Um, and of course, it's the first study. So, we are exploring and looking at the competitive side. I mean, obviously there are so many programs going on in this space, of various natures and so forth. So, so, um, I'm certainly aware of competitors in different forms and shapes. Um, but in terms of monthly dosing in the clinical setting, there's very little there. I mean, Amgen has a program that you're probably aware of, but that's a different approach. And there has also been an announcement regarding Ascendis. But I think that's the early stage.

Jon Garay Alonso
48:35 - 48:37

Okay. Thank you very much.

Operator
48:39 - 48:44

Uh, the next question is from Eric from Carnegie. Please go ahead, Eric.

Jon Garay Alonso
48:46 - 49:13

Yes. Hi. Uh, I have a question, I guess, for Richard. Uh, if you could comment on the average price, how that has changed over the course of 2024. And what do you see in terms of pricing in 2025 in your major geographies? Are there any price cuts in certain markets that you have included in the guidance?

Operator
49:14 - 49:22

You know, the pricing is flat, has been flat for the last couple of years, and we predict it will remain so going forward.

Fredrik Tiberg
49:26 - 49:27

All right. Thank you.

Operator
49:29 - 49:36

There are no more questions at this time. So I hand the word back to you, Fredrik and Richard, for some closing comments.

Fredrik Tiberg
49:37 - 49:53

Yes. Thank you, everybody, for a very good Q&A session. Um, I think it's been a very good year for us. And, um, I'm happy that we have a lot of questions coming up from it. So, uh, Jon, do you have anything? Last comments, Richard.

Jon Garay Alonso
49:53 - 49:56

Thank you, everyone. I'm looking forward to Q1 next year.

Fredrik Tiberg
49:56 - 50:03

Yes, we have Q1 coming up, but it will be in May. So thank you, everybody, and have a great afternoon.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…